Chinese Hepatolgy ›› 2019, Vol. 24 ›› Issue (12): 1357-1373.
• Guideline & Consensus • Previous Articles Next Articles
Received:2019-11-20
Published:2020-03-28
| [1] Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol, 2019, 4:127-134. [2] Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med, 2018, 378:354-369. [3] 国家卫生计生委, 国家发展改革委, 教育部, 等. 中国病毒性肝炎防治规划(2017-2020 年). 中国病毒病杂志, 2018, 8:1-5. [4] WHO. Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization, 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. [5] WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization, 2018. https://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2018/en/. [6] 陈园生, 李黎, 崔富强, 等. 中国丙型肝炎血清流行病学研究. 中华流行病学杂志, 2011, 32:888-891. [7] 庄辉. 中国丙型肝炎感染现状及防治对策研究报告. 北京:人民卫生出版社, 2018. [8] Rao H, Wei L, Lopez-Talavera JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol, 2014, 29:545-553. [9] Chen Y, Yu C, Yin X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect, 2017, 6:e95. [10] European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol, 2015, 63:199-236. [11] Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005, 42:962-973. [12] Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary.Hepatology, 2015, 62:1623-1632. [13] Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Updat, 2018, 37: 17-39. [14] Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med, 1991, 325: 98-104. [15] Corey KE, Mendez-Navarro J, Gorospe EC, et al. Early treatment improves outcomes in acute hepatitis C virus infection: a metaanalysis. J Viral Hepat, 2010, 17: 201-207. [16] Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med, 1999, 340: 1228-1233. [17] Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatolgy, 2001, 34: 809-816. [18] Rao HY, Sun DG, Yang RF, et al. Outcome of hepatitis C virus infection in Chinese paid plasma donors: a 12-19-year cohort study. J Gastroenterol Hepatol, 2012, 27: 526-532. [19] Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 1997, 349: 825-832. [20] Barreiro P, Pineda JA, Rallón N, et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J Infect Dis, 2011, 203: 1629-1636. [21] Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. World J Gastroenterol, 2013, 19: 7896-7909. [22] Heim MH. Innate immunity and HCV. J Hepatol, 2013, 58:564-574. [23] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol, 2018, 69: 461-511. [24] European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol, 2015, 63: 237-264. [25] Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology, 2003, 38: 518-526. [26] 中国肝炎防治基金会, 中华医学会感染病学分会, 中华医学会肝病学分会和中国研究型医院学会肝病专业委员会. 瞬时弹性成像技术诊断肝纤维化专家共识(2018 年更新版). 中华肝脏病杂志, 2019, 27: 182-191. [27] 孙惠川, 王征, 周俭, 等. 2017 年版中国肝癌诊断和治疗规范解读. 实用肿瘤杂志, 2018, 33: 1-3. [28] John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C.Am J Gastroenterol, 2009, 104: 2439-2448. [29] Bourlière M, Pietri O. Hepatitis C virus therapy: no one will be left behind. Int J Antimicrob Agents, 2019, 53: 755-760. [30] Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol, 2018, 53: 557-565. [31] Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology, 2018, 67: 505-513. [32] Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection . N Engl J Med, 2014, 370: 211-221. [33] Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology, 2014, 59:2083-2091. [34] Wei L, Zhang M, Xu M, et al. Daclatasvir and asunaprevir in non-Japanese Asian patients with chronic HCV genotype 1b infection who are ineligible for or intolerant to interferon-alfa therapies with or without ribavirin: phase 3 SVR12 interim results. Hepatology, 2015, 62: 1391A. [35] Wei L, Wang FS, Zhang MX, et al. Daclatasvir plus asunaprevir in treatment-na?ve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol, 2018, 24: 1361-1372. [36] 魏来, 成军, Luo Yan, 等. 在初治和经治丙型肝炎病毒基因1b型慢性感染的非肝硬化亚成年患者中评价奥比帕利联合达塞布韦治疗的有效性和安全性: 随机、双盲、安慰剂对照研究. 中华肝脏病杂志, 2018, 26: 359-364. [37] 魏来, 王贵强, Sarah Kopecky-Bromberg, 等. 在初治和经治丙型肝炎病毒基因1b 型慢性感染的代偿期肝硬化亚洲成年患者中评价奥比帕利和达塞布韦联合利巴韦林治疗的有效性和安全性. 中华肝脏病杂志, 2018, 26: 353-358. [38] Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med, 2014, 370: 1594-1603. [39] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/rombitasvirand dasabuvir with or without ribavirin for HCV. N Engl J Med, 2014, 370: 1983-1992. [40] Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir withribavirin. N Engl J Med, 2014, 370: 1604-1614. [41] Wei L, Jia JD, Wang FS, et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. J Gastroenterol Hepatol, 2019, 34: 12-21. [42] Wei L, Kumada H, Perumalswami PV, et al. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection. J Gastroenterol Hepatol, 2019, 34:1597-1603. [43] Wei L, Xie Q, Hou JL, et al. Ledipasvir/sofosbuvir for treatmentnaive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study. Hepatol Int, 2018, 12:126-132. [44] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med, 2014, 370: 1889-1898. [45] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med, 2014, 370: 1483-1493. [46] Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med, 2014, 370: 1879-1888. [47] Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013, 368: 1878-1887. [48] Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013, 369: 678-679. [49] Liu CJ, Chuang WL, Sheen IS, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology, 2018, 154: 989-997. [50] Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med, 2014, 370: 1993-2001. [51] Wei L, Xie Q, Hou JL, et al. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: results from a phase 3b study in China. J Gastroenterol Hepatol, 2018, 33: 1168-1176. [52] Wei L, Shang J, Ma Y, et al. Efficacy and safety of 12-week interferon-based danoprevir regimen in patients with genotype 1 chronic hepatitis C. J Clin and Trans Hepatol, 2019, 7: 221-225. [53] 魏来. 达诺瑞韦及其联合PR 方案治疗慢性丙型肝炎研究进展. 中华临床感染病杂, 2018, 11: 84-89. [54] Mishra P, Florian J, Qi K, et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology, 2014, 147: 1196-1200. [55] Rao H, Song G, Li G, et al. Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis. J Viral Hepat, 2019. [56] Gao YH, Niu JQ, Kong F, et al. Pan-genotypic regimen of coblopasvir plus sofosbuvir for treatment of chronic hepatitis C in China: a single-arm, open-label, phase 3 trial. AASLD-2019 Poster 1647. [57] Xu X, Feng B, Guan Y, et al. Efficacy and safety of all-oral, 12 week ravidasvir plus ritonavir-boosted danoprevir and ribavirin in treatment-na?ve, non-cirrhotic HCV genotype 1 patients: results from a phase 2/3 clinical trial in China. J Clin Transl Hepatol, 2019, 7: 213-220. [58] 罗碧芬, 金晶兰, 饶慧瑛, 等. 磷酸依米他韦联合索磷布韦治疗慢性丙型肝炎病毒感染的有效性和安全性 . 中华传染病杂志, 2019, 37: 420-429. [59] Meyer IA, Tan SS, Salvadori N, et al. Safety and efficacy of ravidasvir plus sofosbuvir for 12 weeks in non-cirrhotic and 24 weeks in cirrhotic patients with hepatitis C genotypes 1, 2, 3, and 6: the STROM-C-1 phase II/III trial stage 1 results. ILC-2018 LBP-032. [60] AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis, 2018, 67: 1477-1492. [61] Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol, 2016, 1: 122-132. [62] Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med, 2015, 373: 2618-2628. [63] Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology, 2017,66: 371-378. [64] Wirth S, Rosenthal P, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology, 2017, 66: 1102-1110. [65] Mavret U.S Prescribing Information(accessed Apr.2019)https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209394s006lbl.pdf [66] Wei L, Omata M, Lim YS, et al. HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-rsistance associated substitutions in HCV-infection patients in Mainland China. Antiviral Res, 2018, 158: 178-184. [67] Lu J, Feng Y, Chen L, et al. Subtype-specific prevalence of hepatitis C virus NS5A resistance associated substitutions in Mainland China. Front Microbiol, 2019 , 10: 535. [68] Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol, 2019, 71: 660-665. [69] Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology, 2016, 150: 1590-1598. [70] Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet, 2015, 386: 1537-1545. [71] Bruchfeld A, Roth D, Martin P, et al. Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-oflife outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol, 2017, 2: 585-594. [72] Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med, 2017, 377: 1448-1455. [73] Pol S, Pockros P, Pugatch D, et al. Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis. J Hepatol, 2017, 66: S738. [74] Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int, 2016, 29: 999-1007. [75] Kamar N, Marion O, Rostaing L, et al. Efficacy and safety of sofosbuvir-based antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant, 2016, 16: 1474-1479. [76] Agarwal K, Castells L, Mullhaupt B, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol, 2018, 69: 603-607. [77] Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial. Lancet HIV, 2015, 2: e319-327. [78] Monaco S, Ferrari S, Gajofatto A, et al. HCV-related nervous system disorders. Clin Dev Immunol, 2012, 2012: 236148. [79] van der Meer AJ. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?. Expert Rev Gastroenterol Hepatol, 2015, 9: 559-566. [80] Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents. Clin Gastroenterol Hepatol, 2017, 15: 132-136. [81] Wyles D, Saag M, Viani RM, et al.TURQUOISE-I part 1b: ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin for hepatitis C virus infection in HIV-1 coinfected patients on darunavir. J Infect Dis, 2017, 215: 599-605. [82] Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat, 2006, 13: 34-41. [83] Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology, 2003, 37: 60-64. [84] Deterding K, Spinner CD, Schott E, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet acute HCV IV): an openlabel, single-arm, phase 2 study. Lancet Infect Dis, 2017, 17:215-222. [85] Martinello M, Bhagani S, Gane E, et al. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection. J Viral Hepat, 2018, 25: 1180-1188. [86] Izumi N, Takehara T, Chayama K, et al. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviral. Hepatol Int, 2018, 12: 356-367. [87] Wyles D, Weiland O, Yao B, et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol, 2019, 70: 1019-1023. [88] Vermehren J, Susser S, Dietz J, et al. Retreatment of patients who failed DAA-combination therapies: real-world experience from a large hepatitis C resistance database. J Hepatol, 2016, 64: S183-212. [89] Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology, 2018, 154: 976-988,.e4. [90] Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med, 2017, 376: 2134-2146. [91] Dufour JF, Zuckerman E, Zadeikis N, et al. Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis. Gastroenterology, 2017, 152:S1089. [92] 中国肝炎防治基金会, 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎直接抗病毒药物应用中的药物相互作用管理专家共识. 中华肝脏病杂志, 2018, 26: 481-488. [93] Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol, 2017, 67: 1204-1212. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
